← Back to Clinical Trials
Recruiting NCT04512456

Cardiovascular Responses to Exercise in People Living With HIV/AIDS: Effects of Exercise Training

Trial Parameters

Condition HIV Infections
Sponsor Instituto Nacional de Cardiologia de Laranjeiras
Study Type INTERVENTIONAL
Phase N/A
Enrollment 63
Sex ALL
Min Age 30 Years
Max Age 50 Years
Start Date 2024-08-01
Completion 2026-12-31
Interventions
Exercise training

Brief Summary

Patients living with HIV (PLWHIV) have compromised muscle metaboreflex, which can cause exercise intolerance. This randomized controlled clinical trial will verify the effects of regular exercise on autonomic and hemodynamic responses to muscle ergoreflex activation in these patients. PLWHIV without regular physical exercise will be randomly assigned into an exercise training or a control group. The exercise training group will undergo regular physical exercise during 12 weeks (60-min session performed 3 times/wk with moderate intensity), while the control group will keep inactive. Another group consisted of inactive HIV-uninfected group will be included. The primary endpoints will be blood pressure and autonomic markers in response to the Stroop Color-Word Test and the activation of muscle ergoreflex, by means of the post-exercise circulatory arrest (PECA), which will be performed with and without the topical application of a capsaicin-based analgesic balm. Secondary endpoints will include heart rate, peripheral vascular resistance, stroke volume, cardiac output, blood lactate concentration, anthropometrics, and handgrip strength. The active and inactive PLWHIV groups will be evaluated before and after the exercise training, while the healthy group only at baseline.

Eligibility Criteria

Inclusion Criteria for people living with HIV: * diagnosis of HIv infection for at least 5 years; * use of combined antiretroviral therapy for at least 3 years; * asymptomatic and free from opportunistic diseases at enrollment. Exclusion Criteria: * regular physical exercise; * malnutrition; * presence of coronary artery disease, ischemic diseases, pulmonary disease, diabetes, Chagas disease, tuberculosis, heart failure, hypertension; * using pacemakers and/or antidepressant, antiarrhythmic or antihypertensive medication, especially beta-blockers.

Related Trials